Pneumococcal disease in the elderly - What is preventing vaccine efficacy?

被引:20
作者
Rubins, JB
Janoff, EN
机构
[1] Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA
[2] Vet Affairs Med Ctr, Minneapolis, MN USA
关键词
D O I
10.2165/00002512-200118050-00001
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
The effective prevention of Streptococcus pneumoniae infection has a renewed priority in an era in which the emergence of antibacterial-resistant strains has the potential to further compromise efforts to reduce early mortality from invasive pneumococcal infection. Although the 23-valent pneumococcal polysaccharide (PPS) vaccine was approved in the US to prevent respiratory and invasive infection in the elderly and other high-risk populations, the protective efficacy of this vaccine for the growing population of adults aged > 65 years remains controversial. The apparent effectiveness of pneumococcal immunisation in clinical studies of elderly adults has varied depending upon whether a reduction in pneumococcal colonisation, pneumonia, bacteraemia or death was used as an outcome. Clinical studies of vaccine efficacy to date suggest that the current pneumococcal vaccine is 56 to 81% effective at preventing invasive pneumococcal infection, and may have additive benefit to influenza vaccine in preventing community-acquired pneumonia. particularly in elderly adults with an increased risk of serious pneumonia requiring hospitalisation. Possible reasons for incomplete protection from pneumococcal infection after immunisation include infection with non-vaccine serotypes, inadequate or ineffective antibody responses, waning of antibody responses, or compromised nonhumoral host defences. Fur ther studies are needed to determine whether: (i) elderly adults who respond poorly to the 23-valent pneumococcal vaccine can be identified prior to immunisation and targeted for study with improved pneumococcal vaccines; (ii) specific nutrient deficiencies can be identified and corrected to improve the immune responsiveness of elderly adults to the PPS vaccine; (iii) newer protein-conjugate or DNA pneumococcal vaccines may be more uniformly immunogenic for elderly adults; and (iv) whether smoking cessation reduces the risk of invasive pneumococcal infection in elderly adults.
引用
收藏
页码:305 / 311
页数:7
相关论文
共 42 条
[1]   CORRELATION BETWEEN G2M(N) IMMUNOGLOBULIN ALLOTYPE AND HUMAN-ANTIBODY RESPONSE AND SUSCEPTIBILITY TO POLYSACCHARIDE ENCAPSULATED BACTERIA [J].
AMBROSINO, DM ;
SCHIFFMAN, G ;
GOTSCHLICH, EC ;
SCHUR, PH ;
ROSENBERG, GA ;
DELANGE, GG ;
VANLOGHEM, E ;
SIBER, GR .
JOURNAL OF CLINICAL INVESTIGATION, 1985, 75 (06) :1935-1942
[2]  
Austrian R, 1976, Trans Assoc Am Physicians, V89, P184
[3]   PNEUMOCOCCAL VACCINE EFFICACY IN SELECTED POPULATIONS IN THE UNITED-STATES [J].
BOLAN, G ;
BROOME, CV ;
FACKLAM, RR ;
PLIKAYTIS, BD ;
FRASER, DW ;
SCHLECH, WF .
ANNALS OF INTERNAL MEDICINE, 1986, 104 (01) :1-6
[4]   PNEUMOCOCCAL POLYSACCHARIDE VACCINE EFFICACY - AN EVALUATION OF CURRENT RECOMMENDATIONS [J].
BUTLER, JC ;
BREIMAN, RF ;
CAMPBELL, JF ;
LIPMAN, HB ;
BROOME, CV ;
FACKLAM, RR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (15) :1826-1831
[5]   Immune function and vaccine responses in healthy advanced elderly patients [J].
Carson, PJ ;
Nichol, KL ;
O'Brien, J ;
Hilo, P ;
Janoff, EN .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (13) :2017-2024
[6]  
*CDC, 1998, JAMA-J AM MED ASSOC, V280, P1818
[7]   PREVENTING PNEUMOCOCCAL BACTEREMIA IN PATIENTS AT RISK - RESULTS OF A MATCHED CASE-CONTROL STUDY [J].
FARR, BM ;
JOHNSTON, BL ;
COBB, DK ;
FISCH, MJ ;
GERMANSON, TP ;
ADAL, KA ;
ANGLIM, AM .
ARCHIVES OF INTERNAL MEDICINE, 1995, 155 (21) :2336-2340
[8]   Impaired antibody responses to pneumococcal polysaccharide in elderly patients with low serum vitamin B-12 levels [J].
Fata, FT ;
Herzlich, BC ;
Schiffman, G ;
Ast, AL .
ANNALS OF INTERNAL MEDICINE, 1996, 124 (03) :299-+
[9]   Anti-pneumococcal antibody response in normal subjects: A meta-analysis [J].
Go, ES ;
Ballas, ZK .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1996, 98 (01) :205-215
[10]  
HILLEMAN MR, 1981, REV INFECT DIS, V3, pS31